ALK and ROS1 Rearrangements, Coexistence and Treatment in Epidermal Growth Factor Receptor-wild Type Lung Adenocarcinoma: a Multicenter Study of 732 Cases

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2017 Dec 23

PMID 29268402

Citations 17

Authors

Zhengbo Song

Yuhui Zheng

Xuzhou Wang

Haiyan Su

Yiping Zhang

Yong Song

Affiliations

Soon will be listed here.

Abstract

Background: Anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) rearrangements represent two most frequent fusion targets in lung adenocarcinoma. Our study was intended to explore the clinicopathological characteristics, coexistence and treatment of ALK/ROS1-rearranged patients of lung adenocarcinoma without epidermal growth factor receptor (EGFR) mutation.

Methods: Patients with wild-type EGFR mutation were screened for ALK/ROS1 at four domestic hospitals. ALK/ROS1 rearrangements were detected by reverse transcription-polymerase chain reaction (RT-PCR). Progression-free survival (PFS) curve was plotted with the Kaplan-Meier method.

Results: Among 732 eligible cases, ALK and ROS1 rearrangements were detected in 89 (12.2%) and 32 (4.4%) patients respectively. One patient harbored coexisting ALK/ROS1 fusion. Both ALK and ROS1-positive phenotypes were predominantly detected in younger non-smokers. More ALK/ROS1-rearranged patients were correlated with the expressions of TTF1, napsin A and solid predominant adenocarcinoma subtype. Thirty-three ALK and six ROS1 rearrangement patients received crizotinib treatment at an advanced stage. The median PFS was 9.5 months for ALK-positive patients and it was not attained in ROS1-rearranged counterparts.

Conclusions: The frequency of ALK and ROS1 rearrangements is elevated in EGFR-wild-type patients and the phenomenon of coexisting ALK/ROS1 has remained extremely rare. The rearrangements of ALK/ROS1 are correlated with age, smoking status, expressions of TTF1 & napsin A and solid predominant adenocarcinoma subtype.

Citing Articles

Current treatment and novel insights regarding ROS1-targeted therapy in malignant tumors.

Li S, Zhang H, Chen T, Zhang X, Shang G Cancer Med. 2024; 13(8):e7201.

PMID: 38629293 PMC: 11022151. DOI: 10.1002/cam4.7201.

Lung adenocarcinoma patients with -rearranged tumors by sex and smoking intensity.

Peng Y, Ernani V, Liu D, Guo Q, Hopps M, Cappelleri J Heliyon. 2024; 10(7):e28285.

PMID: 38560203 PMC: 10981064. DOI: 10.1016/j.heliyon.2024.e28285.

Analytical validation and clinical utilization of K-4CARE™: a comprehensive genomic profiling assay with personalized MRD detection.

Nguyen Hoang T, Nguyen T, Tran N, Nguyen Hoang V, Thi Dao H, Tran V Front Mol Biosci. 2024; 11:1334808.

PMID: 38404964 PMC: 10886136. DOI: 10.3389/fmolb.2024.1334808.

Progress of non-small-cell lung cancer with rearrangement.

Yang X, Tang Z, Li J, Jiang J, Liu Y Front Mol Biosci. 2024; 10:1238093.

PMID: 38187090 PMC: 10766828. DOI: 10.3389/fmolb.2023.1238093.

Microbiota Diversity in Non-Small Cell Lung Cancer Gut and Mouth Cavity Microbiota Diversity in Non-Small Cell Lung Cancer Patients.

Brisudova A, Bielnikova-Krystofova H, Motyka O, Fritzova D, Katuchova V, Ponikelska N Pol J Microbiol. 2023; 72(4):467-475.

PMID: 38103007 PMC: 10725158. DOI: 10.33073/pjm-2023-044.

References

Sequist L, Soria J, Goldman J, Wakelee H, Gadgeel S, Varga A . Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015; 372(18):1700-9. DOI: 10.1056/NEJMoa1413654. View

Li H, Pan Y, Li Y, Li C, Wang R, Hu H . Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer. 2012; 79(1):8-13. DOI: 10.1016/j.lungcan.2012.09.018. View

Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H . ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer. 2014; 84(2):121-6. DOI: 10.1016/j.lungcan.2014.02.007. View

Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K . Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res. 2015; 4(2):156-64. PMC: 4384213. DOI: 10.3978/j.issn.2218-6751.2014.11.11. View

Eng J, Woo K, Sima C, Plodkowski A, Hellmann M, Chaft J . Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas. J Thorac Oncol. 2015; 10(12):1713-9. PMC: 4760768. DOI: 10.1097/JTO.0000000000000671. View

Solomon B, Mok T, Kim D, Wu Y, Nakagawa K, Mekhail T . First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371(23):2167-77. DOI: 10.1056/NEJMoa1408440. View

Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y . Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res. 2012; 18(7):1947-53. PMC: 3319848. DOI: 10.1158/1078-0432.CCR-11-2511. View

Warth A, Muley T, Dienemann H, Goeppert B, Stenzinger A, Schnabel P . ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases. Histopathology. 2014; 65(2):187-94. DOI: 10.1111/his.12379. View

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

10.

Yang J, Zhang X, Su J, Xu C, Zhou Q, Tian H . Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res. 2014; 20(5):1383-92. DOI: 10.1158/1078-0432.CCR-13-0699. View

11.

Shaw A, Ou S, Bang Y, Camidge D, Solomon B, Salgia R . Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 371(21):1963-71. PMC: 4264527. DOI: 10.1056/NEJMoa1406766. View

12.

Mazieres J, Zalcman G, Crino L, Biondani P, Barlesi F, Filleron T . Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015; 33(9):992-9. DOI: 10.1200/JCO.2014.58.3302. View

13.

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J . Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2009; 11(2):121-8. DOI: 10.1016/S1470-2045(09)70364-X. View

14.

Shaw A, Kim D, Nakagawa K, Seto T, Crino L, Ahn M . Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368(25):2385-94. DOI: 10.1056/NEJMoa1214886. View

15.

Leighl N, Rekhtman N, Biermann W, Huang J, Mino-Kenudson M, Ramalingam S . Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American.... J Clin Oncol. 2014; 32(32):3673-9. PMC: 5321089. DOI: 10.1200/JCO.2014.57.3055. View

16.

Zhou C, Wu Y, Chen G, Feng J, Liu X, Wang C . Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12(8):735-42. DOI: 10.1016/S1470-2045(11)70184-X. View

17.

Wu C, Zhao C, Yang Y, He Y, Hou L, Li X . High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules. J Thorac Oncol. 2015; 10(5):778-783. DOI: 10.1097/JTO.0000000000000487. View

18.

Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y . Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients. Med Oncol. 2013; 30(3):645. DOI: 10.1007/s12032-013-0645-1. View

19.

Zhang X, Zhang S, Yang X, Yang J, Zhou Q, Yin L . Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer. 2010; 9:188. PMC: 2908583. DOI: 10.1186/1476-4598-9-188. View

20.

Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B . Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol. 2010; 28(30):4616-20. PMC: 2974342. DOI: 10.1200/JCO.2010.29.6038. View